RT Journal Article
SR Electronic
T1 Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
DO 10.3174/ajnr.A7134
A1 F. Al-Mufti
A1 K. Amuluru
A1 R. Sahni
A1 K. Bekelis
A1 R. Karimi
A1 J. Ogulnick
A1 J. Cooper
A1 P. Overby
A1 R. Nuoman
A1 A. Tiwari
A1 K. Berekashvili
A1 N. Dangayach
A1 J. Liang
A1 G. Gupta
A1 P. Khandelwal
A1 J.F. Dominguez
A1 T. Sursal
A1 H. Kamal
A1 K. Dakay
A1 B. Taylor
A1 E. Gulko
A1 M. El-Ghanem
A1 S.A. Mayer
A1 C. Gandhi
YR 2021
UL http://www.ajnr.org/content/early/2021/04/22/ajnr.A7134.abstract
AB BACKGROUND AND PURPOSE: Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area.MATERIALS AND METHODS: We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020.RESULTS: Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36–62 years; range, 17–95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%.CONCLUSIONS: Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.COVID-19coronavirus disease 2019CVSTcerebral venous sinus thrombosisCVTcerebral venous thrombosisSARS-CoV-2Severe Acute Respiratory Syndrome coronavirus 2